Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm adjuvant sugemalimab trial after surgery for high-risk renal cell carcinoma
ChiCTR2500100330Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sugemalimab in renal cell carcinoma (RCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Disease-free survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
sugemalimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2500100330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100330.